SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Angela R. Ozburn, Edgardo Falcon, Alan Twaddle, Alexandria L. Nugent, Andrea G. Gillman, Sade M. Spencer, Rachel N. Arey, Shibani Mukherjee, James Lyons-Weiler, David W. Self, Colleen A. McClung, Direct Regulation of Diurnal Drd3 Expression and Cocaine Reward by NPAS2, Biological Psychiatry, 2015, 77, 5, 425

    CrossRef

  2. 2
    Thomas M. Keck, William S. John, Paul W. Czoty, Michael A. Nader, Amy Hauck Newman, Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis, Journal of Medicinal Chemistry, 2015, 150331093158009

    CrossRef

  3. 3
    Charles R. Ashby, Onarae V. Rice, Christian A. Heidbreder, Eliot L. Gardner, The selective dopamine D3 receptor antagonist SB-277011A attenuates drug- or food-deprivation reactivation of expression of conditioned place preference for cocaine in male sprague-dawley rats, Synapse, 2015, 69, 6
  4. 4
    Ying Chen, Rui Song, Ri-Fang Yang, Ning Wu, Jin Li, A novel dopamine D3 receptor antagonist YQA14 inhibits methamphetamine self-administration and relapse to drug-seeking behaviour in rats, European Journal of Pharmacology, 2014, 743, 126

    CrossRef

  5. 5
    Rui Song, Guo-Hua Bi, Hai-Ying Zhang, Ri-Fang Yang, Eliot L. Gardner, Jin Li, Zheng-Xiong Xi, Blockade of D3 receptors by YQA14 inhibits cocaine's rewarding effects and relapse to drug-seeking behavior in rats, Neuropharmacology, 2014, 77, 398

    CrossRef

  6. 6
    Fei Liu, Xiaomei Zhuang, Cuiping Yang, Zheng Li, Shan Xiong, Zhiwei Zhang, Jin Li, Chuang Lu, Zhenqing Zhang, Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction, Biopharmaceutics & Drug Disposition, 2014, 35, 5
  7. 7
    B Jupp, J W Dalley, Convergent pharmacological mechanisms in impulsivity and addiction: insights from rodent models, British Journal of Pharmacology, 2014, 171, 20
  8. 8
    Y. Yan, A.H. Newman, M. Xu, Dopamine D1 and D3 receptors mediate reconsolidation of cocaine memories in mouse models of drug self-administration, Neuroscience, 2014, 278, 154

    CrossRef

  9. 9
    Janet L. Neisewander, Timothy H.C. Cheung, Nathan S. Pentkowski, Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development, Neuropharmacology, 2014, 76, 301

    CrossRef

  10. 10
    Gian Marco Leggio, Giovanni Camillieri, Chiara B M Platania, Alessandro Castorina, Giuseppina Marrazzo, Sebastiano Alfio Torrisi, Christina N Nona, Velia D'Agata, José Nobrega, Holger Stark, Claudio Bucolo, Bernard Le Foll, Filippo Drago, Salvatore Salomone, Dopamine D3 Receptor Is Necessary for Ethanol Consumption: An Approach with Buspirone, Neuropsychopharmacology, 2014, 39, 8, 2017

    CrossRef

  11. 11
    Gian Marco Leggio, Sebastiano Alfio Torrisi, Alessandro Castorina, Chiara Bianca Maria Platania, Agata Antonia Rita Impellizzeri, Annamaria Fidilio, Filippo Caraci, Claudio Bucolo, Filippo Drago, Salvatore Salomone, Dopamine D3 receptor-dependent changes in alpha6 GABAA subunit expression in striatum modulate anxiety-like behaviour: Responsiveness and tolerance to diazepam, European Neuropsychopharmacology, 2014,

    CrossRef

  12. 12
    Neil E. Paterson, Frank Vocci, Rajkumar J. Sevak, Eric Wagreich, Edythe D. London, Dopamine D3 receptors as a therapeutic target for methamphetamine dependence, The American Journal of Drug and Alcohol Abuse, 2014, 40, 1, 1

    CrossRef

  13. You have free access to this content13
    Ariadna Forray, Mehmet Sofuoglu, Future pharmacological treatments for substance use disorders, British Journal of Clinical Pharmacology, 2014, 77, 2
  14. 14
    S Carnicella, G Drui, S Boulet, C Carcenac, M Favier, T Duran, M Savasta, Implication of dopamine D3 receptor activation in the reversion of Parkinson’s disease-related motivational deficits, Translational Psychiatry, 2014, 4, 6, e401

    CrossRef

  15. 15
    Samantha R. Cote, Eldo V. Kuzhikandathil, In vitro and in vivo characterization of the agonist-dependent D3 dopamine receptor tolerance property, Neuropharmacology, 2014, 79, 359

    CrossRef

  16. 16
    Bernard Le Foll, Patricia Di Ciano, Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction, European Neuropsychopharmacology, 2014,

    CrossRef

  17. 17
    Bernard Le Foll, Alan A. Wilson, Ariel Graff, Isabelle Boileau, Patricia Di Ciano, Recent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug development, Frontiers in Pharmacology, 2014, 5,

    CrossRef

  18. 18
    Jianyong Chen, Beth Levant, Cheng Jiang, Thomas M. Keck, Amy Hauck Newman, Shaomeng Wang, Tranylcypromine Substitutedcis-Hydroxycyclobutylnaphthamides as Potent and Selective Dopamine D3Receptor Antagonists, Journal of Medicinal Chemistry, 2014, 57, 11, 4962

    CrossRef

  19. 19
    Thomas M. Keck, Caitlin Burzynski, Lei Shi, Amy Hauck Newman, Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse, 2014,

    CrossRef

  20. 20
    Bernard Le Foll, Ginetta Collo, Eugenii A. Rabiner, Isabelle Boileau, Emilio Merlo Pich, Pierre Sokoloff, Dopamine, 2014,

    CrossRef

  21. 21
    Zheng-Xiong Xi, Xia Li, Jie Li, Xiao-Qing Peng, Rui Song, József Gaál, Eliot L. Gardner, Blockade of dopamine D3 receptors in the nucleus accumbens and central amygdala inhibits incubation of cocaine craving in rats, Addiction Biology, 2013, 18, 4
  22. 22
    Fabrizio Micheli, Christian Heidbreder, Dopamine D3 receptor antagonists: a patent review (2007 – 2012), Expert Opinion on Therapeutic Patents, 2013, 23, 3, 363

    CrossRef

  23. 23
    Rui Song, Hai-Ying Zhang, Xiao-Qing Peng, Rui-Bin Su, Ri-Fang Yang, Jin Li, Zheng-Xiong Xi, Eliot L. Gardner, Dopamine D3 receptor deletion or blockade attenuates cocaine-induced conditioned place preference in mice, Neuropharmacology, 2013, 72, 82

    CrossRef

  24. 24
    Y. Yan, H. Kong, E.J. Wu, A.H. Newman, M. Xu, Dopamine D3 receptors regulate reconsolidation of cocaine memory, Neuroscience, 2013, 241, 32

    CrossRef

  25. 25
    Nancy K Mello, Peter A Fivel, Stephen J Kohut, Jack Bergman, Effects of Chronic Buspirone Treatment on Cocaine Self-Administration, Neuropsychopharmacology, 2013, 38, 3, 455

    CrossRef

  26. 26
    Christian Heidbreder, Rationale in support of the use of selective dopamine D3 receptor antagonists for the pharmacotherapeutic management of substance use disorders, Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 2, 167

    CrossRef

  27. 27
    Rongrong Hu, Rui Song, Rifang Yang, Ruibin Su, Jin Li, The dopamine D3 receptor antagonist YQA14 that inhibits the expression and drug-primed reactivation of morphine-induced conditioned place preference in rats, European Journal of Pharmacology, 2013, 720, 1-3, 212

    CrossRef

  28. 28
    R. Song, H.-Y. Zhang, X. Li, G.-H. Bi, E. L. Gardner, Z.-X. Xi, Increased vulnerability to cocaine in mice lacking dopamine D3 receptors, Proceedings of the National Academy of Sciences, 2012, 109, 43, 17675

    CrossRef

  29. 29
    Amy Hauck Newman, Brandi L. Blaylock, Michael A. Nader, Jack Bergman, David R. Sibley, Phil Skolnick, Medication discovery for addiction: Translating the dopamine D3 receptor hypothesis, Biochemical Pharmacology, 2012, 84, 7, 882

    CrossRef

  30. 30
    T.H.C. Cheung, B.C. Nolan, L.R. Hammerslag, S.M. Weber, J.P. Durbin, N.A. Peartree, R.H. Mach, R.R. Luedtke, J.L. Neisewander, Phenylpiperazine derivatives with selectivity for dopamine D3 receptors modulate cocaine self-administration in rats, Neuropharmacology, 2012, 63, 8, 1346

    CrossRef

  31. 31
    Onarae V. Rice, Jay Patrick, Charles D. Schonhar, Haoran Ning, Charles R. Ashby, The effects of the preferential dopamine D3 receptor antagonist S33138 on ethanol binge drinking in C57BL/6J mice, Synapse, 2012, 66, 11